# US 2026/0076931 A1 · L-dopa microbiome therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076931 A1
- Document ID: US20260076931A1
- Status: Published application
- Kind: A1
- Application number: 19/395,786
- Filed: 2025-11-20
- Published: 2026-03-19
- Earliest claimed: 2018-02-27
- Assignees: Iowa State University Research Foundation, Inc.
- Applicants: Iowa State University Research Foundation, Inc.
- Inventors: ANUMANTHA G. KANTHASAMY; Ahmed Abdalla; Gregory Phillips; Nicholas John Backes
- Web page: https://patentgrep.com/patent/US20260076931A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 9/0073: {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and/or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.

## Claims

### Claim 1

An hpaB and hpaC nucleotide sequence comprising SEQ ID NO: 1 and 2 or as set forth in SEQ ID NO: 3 operably linked to a heterologous promoter sequence.

### Claim 2 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NO: 4.

### Claim 3 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 5.

### Claim 4 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 6.

### Claim 5 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence further includes a termination sequence.

### Claim 6 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence is an expression vector.

### Claim 7

An hpaB nucleotide sequence comprising SEQ ID NO: 1 or as present in SEQ ID NO: 3 operably linked to a heterologous promoter.

### Claim 8 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NO: 4.

### Claim 9 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 5.

### Claim 10 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 6.

### Claim 11 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence further includes a termination sequence.

### Claim 12 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence is an expression vector.

### Claim 13

A hpaC nucleotide sequence comprising SEQ ID NO:2 or as present in SEQ ID NO: 3 operably linked to a heterologous promoter.

### Claim 14 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NO: 4.

### Claim 15 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 5.

### Claim 16 (depends on 1)

The nucleotide sequence of claim 1 wherein said heterologous promoter sequence comprises SEQ ID NOs: 6.

### Claim 17 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence further includes a termination sequence.

### Claim 18 (depends on 1)

The nucleotide sequence of claim 1 wherein said sequence is an expression vector.

### Claim 19 (depends on 1)

The hpaB and hpaC nucleotide sequence of claim 1 wherein one of said sequences is at least about 90% homologous to SEQ ID NOS: 1, 2 or 3, operably linked to a heterologous promoter sequence.

### Claim 20 (depends on 19)

The sequence of claim 19 wherein said promoter is one or more of SEQ ID NOS 4-6.